Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Abstract Background Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still relapse and there are currently no clear therapeutic options in post-CAR-T...

Full description

Bibliographic Details
Main Authors: Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina, Sundar Jagannath, Poulikos I. Poulikakos, Samir Parekh, Alessandro Laganà
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Journal of Hematology & Oncology
Subjects:
BCMA CAR-T relapse
BRAF (V600E)
MAPK inhibition
Clonality
RNA-seq
Whole-exome sequencing
Online Access:https://doi.org/10.1186/s13045-022-01330-3

Similar Items

Similar Items